clopidogrel winthrop clopidogrel (as hydrogen sulfate) 300 mg tablet blister pack
sanofi-aventis australia pty ltd - clopidogrel hydrogen sulfate -
clopidogrel sanofi clopidogrel (as hydrogen sulfate) 75 mg tablet blister pack
sanofi-aventis australia pty ltd - clopidogrel hydrogen sulfate -
clopidogrel/aspirin sandoz 75/100 clopidogrel (as hydrogen sulfate) and aspirin 75 mg/100 mg uncoated tablet blister pack
sandoz pty ltd - aspirin,clopidogrel hydrogen sulfate -
clopidogrel rbx clopidogrel (as hydrogen sulfate) 75 mg tablet blister pack
sun pharma anz pty ltd - clopidogrel hydrogen sulfate -
clopidogrel ranbaxy clopidogrel (as hydrogen sulfate) 75 mg tablet blister pack
sun pharma anz pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hydrogenated castor oil; microcrystalline cellulose; lactose monohydrate; macrogol 6000; hyprolose; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.
clopidogrel ran clopidogrel (as hydrogen sulfate) 75 mg tablet blister pack
sun pharma anz pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hydrogenated castor oil; lactose monohydrate; macrogol 6000; microcrystalline cellulose; hyprolose; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.
cloap 75/100 clopidogrel (as hydrogen sulfate) and aspirin 75 mg/100 mg uncoated tablet blister pack
medis pharma pty ltd - aspirin, quantity: 100 mg; clopidogrel hydrogen sulfate, quantity: 97.87 mg (equivalent: clopidogrel, qty 75 mg) - tablet - excipient ingredients: lactose; hydrogenated castor oil; microcrystalline cellulose; crospovidone; glycerol dibehenate; colour - clopidogrel/aspirin is a fixed-dose combination product.,clopidogrel/aspirin is intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel/aspirin is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent); st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel/aspirin has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.
duo plavix 75 mg/75 mg clopidogrel (as hydrogen sulfate)/aspirin tablet blister pack
sanofi-aventis australia pty ltd - aspirin,clopidogrel hydrogen sulfate -
auro-clopidogrel 75 clopidogrel (as hydrogen sulfate) 75mg tablet blister pack
arrotex pharmaceuticals pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hyprolose; hydrogenated castor oil; mannitol; microcrystalline cellulose; macrogol 6000; crospovidone; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.,acute coronary syndrome,clopidogrel is indicated in combination with aspirin for patients with:,? unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent).,? st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.
auro-clopidogrel 75 clopidogrel (as hydrogen sulfate) 75mg tablet bottle
arrotex pharmaceuticals pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hyprolose; crospovidone; microcrystalline cellulose; hydrogenated castor oil; mannitol; macrogol 6000; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.,acute coronary syndrome,clopidogrel is indicated in combination with aspirin for patients with:,? unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent).,? st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.